Catalogue Number: AB03423-1.1-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | CSL; αCSL; Apical complex glycoprotein, CSL (circumsporozoite-like) antigen |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Mouse |
| Clone: | 3E2 |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was generated by immunizing mice with GP25-200 of Cryptosporidium parvum. |
| Application: | ELISA, EM, WB |
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Apical complex glycoprotein antigen of Cryptosporidium parvum is critical to infectivity and targets protective immunity. This antibody exhibited morphologic changes in sporozoites and merozoites characterized by rapid and progressive formation, posterior movement, and release of membranous Ag-mAb precipitates. This antibody was capable of recognizing 46-770 kDa sporozoite antigens and 1300 kDa antigen soluble glycoprotein exoantigen (CSL) expressed by merozoites in a western blot (PMID: 9029117). This antibody elicited circumsporozoite precipitate (CSP)-like reaction which is characterized by the progressive posterior formation and release of membranous antigen-MAb complexes, after which zoites are rendered noninfective. This antibody is capable of neutralizing C. parvum in vitro and also capable of passively protecting against oocyst challenge and infection in vivo. The identification of sporozoite-neutralizing antibody was done using ELISA (PMID: 10768951). This antibody was reported to be highly effective in in reducing, but not eliminating, persistent C. parvum infection (PMID: 11796330). This antibody in combination with PLA2 or LL37 was also used in the generation of a biocide fusion proteins to kill C. parvum sporozoites in vitro and in vivo (PMID: 20086143).
This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgM format for improved compatibility with existing reagents assays and techniques.